Shionogi Europe is a new healthcare company, launched approximately 130 years after the organisation was founded (1878) by Gisaburo Shiono SR. in Doshomachi, Osaka, Japan. The company has grown to become a major research-driven pharmaceutical company dedicated to placing the highest value on patient care.
We are guided by a simple but powerful principle: follow the needs of the patient and the community that surrounds them. This means ensuring that the real-life challenges patients face everyday remain the primary purpose behind R&D, which we believe is a more encouraging way to create clinically-meaningful therapies.
Products and services
We are a research-led organisation, defined by a distinct openness and close partnership approach to creating vaccines and medicines spanning pain, infectious diseases, metabolic disorders, women’s health and oncology.
Our development approach goes hand in hand with the collaborative drug discovery process at the heart of Shionogi. We have an impressive track record of fostering long-term industry partnerships built on trust and a mutual ambition to develop innovative medicines that address unmet medical needs. In 1998 Shionogi licensed one of its new molecules, which later became Crestor (rosuvastatin) to AstraZeneca and still markets this product in Japan today. Other important discoveries include Tivicay and Triumeq, new anti-HIV drugs now marketed by ViiV Healthcare.
Contact
Address: 33 Kingsway, London WC2B 6UF
Tel: +44-203-053-4200
Web: www.shionogi.eu
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
